open access

Ahead of print
Case report
Published online: 2022-04-06
Get Citation

Long-term overall survival in a patient with non-small cell lung cancer with KRAS mutation — case report

Izabela Chmielewska1
DOI: 10.5603/OCP.2022.0006
Affiliations
  1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

open access

Ahead of print
CASE REPORTS
Published online: 2022-04-06

Abstract

The prognosis of patients with metastatic non-small cell lung cancer depends not only on the general condition and stage of the disease but also on the treatment method. Management of lung cancer in stage 4, usually requires a multidisciplinary approach. Frequently in the treatment process, we combine local and systemic treatment. By detecting new therapeutic targets, we can incorporate new elements of therapy. In the described case, the treatment sequence: chemotherapy, immunotherapy, targeted treatment combined with symptomatic local treatment resulted in prolonged survival time and maintaining a good quality of life. The new molecule sotorasib is a drug targeting the G12C mutation in the Kirsten rat sarcoma virus (KRAS) gene approved by the FDA and EMA.

Abstract

The prognosis of patients with metastatic non-small cell lung cancer depends not only on the general condition and stage of the disease but also on the treatment method. Management of lung cancer in stage 4, usually requires a multidisciplinary approach. Frequently in the treatment process, we combine local and systemic treatment. By detecting new therapeutic targets, we can incorporate new elements of therapy. In the described case, the treatment sequence: chemotherapy, immunotherapy, targeted treatment combined with symptomatic local treatment resulted in prolonged survival time and maintaining a good quality of life. The new molecule sotorasib is a drug targeting the G12C mutation in the Kirsten rat sarcoma virus (KRAS) gene approved by the FDA and EMA.

Get Citation

Keywords

non-small-cell lung cancer; KRAS mutation; sotorasib

About this article
Title

Long-term overall survival in a patient with non-small cell lung cancer with KRAS mutation — case report

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Case report

Published online

2022-04-06

Page views

204

Article views/downloads

101

DOI

10.5603/OCP.2022.0006

Keywords

non-small-cell lung cancer
KRAS mutation
sotorasib

Authors

Izabela Chmielewska

References (3)
  1. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25): 2371–2381.
  2. Krawczyk P. Amerykańskie zalecenia dotyczące badań genetycznych w kwalifikacji chorych na raka płuca do terapii inhibitorami kinaz tyrozynowych . Onkol Prakt Klin Edu. 2019; 5(3): 197–206.
  3. Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021; 32(9): 1101–1110.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl